SEC Form 10-K filed by Aprea Therapeutics Inc.
$APRE
Biotechnology: Pharmaceutical Preparations
Health Care
Unavailable
Unavailable
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/20/2021 | Neutral → Underweight | JP Morgan | |
| 8/16/2021 | Buy → Hold | Berenberg | |
| 8/16/2021 | $6.00 → $4.00 | Neutral | HC Wainwright & Co. |
| 8/13/2021 | $6.00 → $5.00 | Sector Perform | RBC Capital |
| 8/13/2021 | $5.00 → $3.00 | Equal-Weight → Underweight | Morgan Stanley |
ACESOT-1051 trial evaluating WEE1 kinase inhibitor APR-1051 now enrolling patients in Cohort 5; open label safety and efficacy data expected H2 2025 Twice daily (BID) dosing regimen in ongoing ABOYA-119 trial expected to maximize clinical benefit of ATR inhibitor ATRN-119; plan to complete dose escalation H2 2025 $22.8 million in cash and cash equivalents as of December 31, 2024 DOYLESTOWN, Pa., March 25, 2025 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE) ("Aprea", or the "Company"), a clinical-stage biopharmaceutical company developing innovative treatments that exploit specific cancer cell vulnerabilities while minimizing damage to healthy cells, today reported financial
DOYLESTOWN, Pa., March 11, 2025 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE) ("Aprea", or the "Company"), a clinical-stage biopharmaceutical company developing innovative treatments that exploit specific cancer cell vulnerabilities while minimizing damage to healthy cells, announced today that it has entered into a Material Transfer Agreement (MTA) with MD Anderson Cancer Center. Under the agreement, Aprea will supply its proprietary WEE1 kinase inhibitor, APR-1051, to support preclinical research aimed at exploring its potential in treating HPV+ and HPV- head and neck squamous cell carcinoma (HNSCC) expressing genomic markers of replication stress. The agreement will enable
DOYLESTOWN, Pa., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE) ("Aprea", or the "Company"), a clinical-stage biopharmaceutical company developing innovative treatments that exploit specific cancer cell vulnerabilities while minimizing damage to healthy cells, today provided an update on its existing patent portfolio. "Our strong patent portfolio reflects our commitment to innovation and leadership in the field of DNA Damage Response therapeutics," said Oren Gilad, Ph.D., President and Chief Executive Officer of Aprea. "Intellectual property is an essential component of Aprea's strategy, enabling us to advance first in class and best in class oncology treatments
4 - Aprea Therapeutics, Inc. (0001781983) (Issuer)
4 - Aprea Therapeutics, Inc. (0001781983) (Issuer)
4 - Aprea Therapeutics, Inc. (0001781983) (Issuer)
4 - Aprea Therapeutics, Inc. (0001781983) (Issuer)
4 - Aprea Therapeutics, Inc. (0001781983) (Issuer)
4 - Aprea Therapeutics, Inc. (0001781983) (Issuer)
10-K - Aprea Therapeutics, Inc. (0001781983) (Filer)
8-K - Aprea Therapeutics, Inc. (0001781983) (Filer)
SCHEDULE 13G/A - Aprea Therapeutics, Inc. (0001781983) (Subject)
DOYLESTOWN, Pa., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE) ("Aprea", or the "Company"), a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced that it has engaged Philippe Pultar, MD as its senior medical advisor to support Aprea with developing and advancing APR-1051, Aprea's potential best in class WEE1 inhibitor. Dr. Pultar is a seasoned pharmaceutical executive with extensive experience in oncology, including the development of a WEE1 inhibitor (azenosertib) from early to late-stage clinical development. Dr. Pultar has vast experience in clinical development within both large and early-stag
Brings proven leadership and successful track record to Halda as the company enters the next stage of growth as clinical-stage company Halda Therapeutics, a biotechnology company developing a novel class of cancer therapies called RIPTAC™ (Regulated Induced Proximity TArgeting Chimeras) therapeutics, today announced that it has appointed Christian Schade as President and Chief Executive Officer and a member of the Board of Directors. Chris brings more than 20 years of public and private pharmaceutical and biotechnology industry experience, including building, financing and leading biotechnology companies through the clinical stages of pipeline development and formation of value-creating de
Chris Schade appointed as Board ChairpersonLynne Parshall, Robert Plenge, M.D., Ph.D., and Nancy Simonian, M.D., appointed to Board of DirectorsCAMBRIDGE, Mass., July 17, 2024 /PRNewswire/ -- Alltrna, a Flagship Pioneering company unlocking transfer RNA (tRNA) biology and pioneering tRNA therapeutics to regulate the protein universe and resolve disease, today announced the appointment of Chris Schade, Growth Partner at Flagship Pioneering, as Chairperson of the Board, succeeding Noubar Afeyan, Ph.D., Co-Founder of Alltrna and Founder and CEO of Flagship Pioneering. In addition, Alltrna also announced the appointments to the company's Board of Directors of Lynne Parshall, founding Chief Opera
JP Morgan downgraded Aprea Therapeutics from Neutral to Underweight
Berenberg downgraded Aprea Therapeutics from Buy to Hold
HC Wainwright & Co. reiterated coverage of Aprea Therapeutics with a rating of Neutral and set a new price target of $4.00 from $6.00 previously
BOSTON, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE), a biopharmaceutical company focused on developing and commercializing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (DDR) pathways today reported financial results for the three and six months ended June 30, 2022 and provided a business update. "This is an exciting time for Aprea as we advance our ATR program into clinical development this year, continue to progress our WEE1 program toward IND submission and leverage our unique discovery platform capabilities to build for future success," said Oren Gilad, Ph.D., President and Chief Executive Officer of Aprea. "We believe o
BOSTON, May 16, 2022 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics targeting DNA damage response pathways today announced that it has acquired Atrin Pharmaceuticals Inc. ("Atrin") and reported financial results for the three months ended March 31, 2022. Business Operations Update: On May 16, 2022 Aprea completed the acquisition of Atrin, a privately held biotechnology company focused on the discovery and development of novel therapeutics targeting proteins in the DNA damage response, or DDR, pathway in oncology through synthetic lethality. The Company believes its cash and cash
BOSTON, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor protein, p53, today announced that the U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on its clinical trials of eprenetapopt in combination with azacitidine in its myeloid malignancy programs. The partial clinical hold does not apply to the Company's ongoing clinical trials in lymphoid malignancies and solid tumors, or the APR-548 clinical trial. There are approximately 20 patients currently receiving eprenetapopt in combination with azacitidine i
SC 13G - Aprea Therapeutics, Inc. (0001781983) (Subject)
SC 13G - Aprea Therapeutics, Inc. (0001781983) (Subject)
SC 13G/A - Aprea Therapeutics, Inc. (0001781983) (Subject)